Jan 30 2008
Palomar Medical Technologies, Inc., a leading researcher and developer of light-based systems for cosmetic treatments, announced today that it will unveil two new fractional handpieces at the 66th Annual Meeting of the American Academy of Dermatology (AAD) in San Antonio, Texas from February 2nd to 4th. Management will be available at this time for investor demonstrations and to discuss Palomar's full line of products in booth #2121 at the Henry B. Gonzalez Convention Center.
Palomar's new Lux2940(TM) fractional ablative laser handpiece is a sophisticated, single-treatment skin resurfacing device which allows the practitioner to tailor the level of skin tightening based on the patient's needs. Three treatment modes are available: short pulse for pure ablation with the fastest treatment times and quickest recovery; long pulse for more coagulation around the ablation columns; and a dual mode for a short pulse / long pulse automatic sequence for deeper corrections. The Lux2940(TM) microfractional technology preserves portions of healthy tissue surrounding the treatment zone, fostering unprecedented rates of reepithelialization and lower patient downtime, with significantly less pain than traditional ablative laser procedures.
Palomar's other new handpiece, the Lux1440(TM) is a fractional, non- ablative skin resurfacing handpiece that operates much like the popular Lux1540(TM), but with faster treatment times. Specifically, licensed practitioners are performing effective full-face treatments in about 12 minutes. As compared to other skin resurfacing devices, the Lux1440(TM) is perfect for a series of "gentler" skin resurfacing treatments, where patient comfort is a priority and little to no downtime a must.
Both the Lux2940(TM) handpiece and the Lux1440(TM) handpiece operates with the StarLux(R) 500 Laser and Pulsed Light System, a single platform with a full suite of aesthetic applications including hair removal, leg vein clearance, acne management and pigmented lesion treatments, and fractional non-ablative skin resurfacing.
Chief Executive Officer Joseph P. Caruso commented, "We are very excited about these new product introductions, which not only reflect the advancement of Palomar technology, but compliment our existing suite of products. Fractional technology continues to provide superior results and now with both ablative and non-ablative options, patients are able to independently select a treatment modality that fits their lifestyle. Our desire to provide the best user experience, facilitated and supported by our ongoing investment in technology, is a primary driver for Palomar. We believe there is a great need for this technology and will continue to produce innovative and reliable products that meet the demands of our customers."